Literature DB >> 21422801

Expression of estrogen receptor α and growth factors in human prolactinoma and its correlation with clinical features and gender.

H Lv1, C Li, S Gui, Y Zhang.   

Abstract

BACKGROUND: Many studies demonstrate that growth factors play an important role in the pathogenesis of prolactinoma induced by estrogen. The effects of estrogen are mainly mediated through its nuclear receptor (ERα); however, expression of ERα and growth factors in prolactinoma and healthy pituitary and their relationship remain obscure. AIM: To obtain new insights regarding the expression differences of these factors and their relationship and to investigate the correlation between gender and clinical features in patients with prolactinoma. SUBJECTS AND METHODS: A total of 21 human prolactinomas and 6 healthy human pituitaries were examined for mRNA expression of ERα, basic fibroblast growth factor (bFGF), transforming growth factor α (TGFα), TGFβ1, TGFβ3, and TGFβ receptor type II (TGFβRII) by means of real-time PCR. Patient clinical data was also analyzed.
RESULTS: Both PRL level and tumor volume of the male patient group were higher than that of the female patient group. There was a significant correlation between PRL level and tumor volume in the total patient group. Expression of ERα, bFGF, TGFα, and TGFβ3 mRNA levels of the patient group were significantly different from that of the control group. A significant correlation between ERα mRNA levels and PRL levels, tumor volume, TGFβ1 mRNA levels in the total patient group were found.
CONCLUSIONS: PRL level and tumor volume have a significant difference between genders in prolactinoma patients. ERα and some growth factors may be involved in the tumorigenesis of prolactinoma. ERα could potentially be an effective therapy target for treating prolactinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21422801     DOI: 10.3275/7607

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  32 in total

1.  Ligand-independent Activation of Steroid Receptors: New Roles for Old Players.

Authors: 
Journal:  Trends Endocrinol Metab       Date:  1999-03       Impact factor: 12.015

Review 2.  Growth factors in development, transformation, and tumorigenesis.

Authors:  M Cross; T M Dexter
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

3.  ER beta: identification and characterization of a novel human estrogen receptor.

Authors:  S Mosselman; J Polman; R Dijkema
Journal:  FEBS Lett       Date:  1996-08-19       Impact factor: 4.124

4.  Two separate mechanisms for ligand-independent activation of the estrogen receptor.

Authors:  M K El-Tanani; C D Green
Journal:  Mol Endocrinol       Date:  1997-06

Review 5.  Cell proliferation of estrogen-sensitive cells: the case for negative control.

Authors:  A M Soto; C Sonnenschein
Journal:  Endocr Rev       Date:  1987-02       Impact factor: 19.871

6.  Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study.

Authors:  E Delgrange; J Trouillas; D Maiter; J Donckier; J Tourniaire
Journal:  J Clin Endocrinol Metab       Date:  1997-07       Impact factor: 5.958

7.  Direct arterial vascularization of estrogen-induced prolactin-secreting anterior pituitary tumors.

Authors:  K A Elias; R I Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

Review 8.  Growth factors and the anterior pituitary.

Authors:  J Webster; M F Scanlon
Journal:  Baillieres Clin Endocrinol Metab       Date:  1991-12

9.  Reduction in the expression and action of transforming growth factor beta 1 on lactotropes during estrogen-induced tumorigenesis in the anterior pituitary.

Authors:  M Pastorcic; A De; N Boyadjieva; W Vale; D K Sarkar
Journal:  Cancer Res       Date:  1995-11-01       Impact factor: 12.701

10.  Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol.

Authors:  D M Ignar-Trowbridge; M Pimentel; M G Parker; J A McLachlan; K S Korach
Journal:  Endocrinology       Date:  1996-05       Impact factor: 4.736

View more
  10 in total

Review 1.  Clinical review: Pituitary carcinoma: difficult diagnosis and treatment.

Authors:  Anthony P Heaney
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

2.  Aromatase cytochrome P450 enzyme expression in prolactinomas and its relationship to tumor behavior.

Authors:  Hakan Akinci; Aysegul Kapucu; Kadriye Akgun Dar; Ozlem Celik; Banu Tutunculer; Gozde Sirin; Buge Oz; Nurperi Gazioglu; Haluk Ince; Süheyla Aliustaoglu; Pinar Kadioglu
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

3.  Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study.

Authors:  Winnie Liu; Roula Shraiky Zahr; Shirley McCartney; Justin S Cetas; Aclan Dogan; Maria Fleseriu
Journal:  Pituitary       Date:  2018-10       Impact factor: 4.107

Review 4.  Molecular Network Basis of Invasive Pituitary Adenoma: A Review.

Authors:  Qi Yang; Xuejun Li
Journal:  Front Endocrinol (Lausanne)       Date:  2019-01-24       Impact factor: 5.555

5.  A Coexisting Pilocytic Astrocytoma and a Prolactinoma: A Case Report of Collision Tumors and Literature Review.

Authors:  Antonia Malli; Savvas Melissaris; Anastasia Dimitriadi; Theodosia Choreftaki; Nikolaos Georgakoulias
Journal:  Cureus       Date:  2019-06-17

6.  Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.

Authors:  Zhengzheng Xiao; Xiaoli Yang; Kun Zhang; Zebin Liu; Zheng Shao; Chaojun Song; Xiaobin Wang; Zhengwei Li
Journal:  Int J Med Sci       Date:  2020-10-23       Impact factor: 3.738

Review 7.  Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications.

Authors:  Betina Biagetti; Rafael Simò
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

8.  Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts.

Authors:  Jun Gao; Yang Liu; Gaijing Han; Kan Deng; Xiaohai Liu; Xinjie Bao; Ming Feng; Yong Yao; Wei Lian; Bing Xing; Xiang Lv; Renzhi Wang
Journal:  J Cell Mol Med       Date:  2018-10-18       Impact factor: 5.310

Review 9.  Pituitary Hyperplasia, Hormonal Changes and Prolactinoma Development in Males Exposed to Estrogens-An Insight From Translational Studies.

Authors:  Branka Šošić-Jurjević; Vladimir Ajdžanović; Dragana Miljić; Svetlana Trifunović; Branko Filipović; Sanja Stanković; Sergey Bolevich; Vladimir Jakovljević; Verica Milošević
Journal:  Int J Mol Sci       Date:  2020-03-16       Impact factor: 5.923

10.  17β-estradiol binding to ERα promotes the progression of prolactinoma through estrogen-response element-induced CaBP-9k up-regulation.

Authors:  Jun Liu; Hao Han; Wenpeng Lu; Gaoyang Fan
Journal:  Biosci Rep       Date:  2020-01-31       Impact factor: 3.840

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.